ABSTRACT

Company name: Matricelf

Website: www.matricelf.com

CEO name: Gil Hakim

CATEGORY: Biotech/Pharma

SESSION: Beyond Bones and Screws: Rethinking Orthopedic Repair.

Executive Summary: Matricelf (TASE: MTLF) targets chronic complete spinal cord injury, a high unmet need with no restorative therapies. A first in class program with value inflection at FIH in 2027 ahead of a NASDAQ dual listing. Addressing a $30B+ US market. IND enabling stage with FDA accepted preclinical data and GMP readiness. Over $25m raised. Leadership brings IPO, M&A, and global pharma experience. **Investment Rational:** Investing now is attractive due to pre FIH entry at a de risked IND enabling stage, ahead of multiple catalysts including NASDAQ dual listing, IND submission, and first human interim readouts.

Core Technology: Autologous engineered tissue implants from patient derived cells, bioengineered into functional 3D neural constructs designed to integrate with the injured spinal cord. Uniqueness comes from low immunogenicity, structured tissue rather than cell suspensions, and focus on chronic injury, rebuilding what is lost instead of modulating what remains. Value lies in potential durable recovery and premium reimbursement.

Product Profile: Product is a single implantation autologous neural tissue implant for chronic complete SCI ASIA A. Status is IND enabling and GMP manufacturing readiness for First in Human early 2027. Market begins with $3.2B capacity and expands to $15B chronic population (U.S. market). Next 12 months: MoH and IRB approvals, FDA IND submission, manufacturing scale up, first patient enrolled in late 2026 and treated in early 2027. Partnerships after 2027 data readouts. **Pipeline:** extends the platform to TBI, stroke, and Parkinson disease through licensing.

Business Strategy: Matricelf will apply its autologous neural tissue platform first in chronic complete SCI through controlled GMP manufacturing and specialized surgical centers. Short term revenues will come from licensing the platform for additional indications and strategic partnerships. Long term revenues will be driven by premium priced SCI commercialization, center of excellence expansion, and value based reimbursement tied to durable functional improvement and reduced lifetime care costs

What's Next? Complete IND enabling studies and submit IND to FDA, secure MoH and IRB approvals, and initiate First in Human in early 2027 with interim readouts. Advance GMP manufacturing scale up and pursue RMAT and Breakthrough designations. Strengthen clinical and manufacturing teams. Execute financing aligned with clinical milestones and planned NASDAQ dual listing.